[go: up one dir, main page]

WO2019031729A3 - Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis - Google Patents

Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis Download PDF

Info

Publication number
WO2019031729A3
WO2019031729A3 PCT/KR2018/008325 KR2018008325W WO2019031729A3 WO 2019031729 A3 WO2019031729 A3 WO 2019031729A3 KR 2018008325 W KR2018008325 W KR 2018008325W WO 2019031729 A3 WO2019031729 A3 WO 2019031729A3
Authority
WO
WIPO (PCT)
Prior art keywords
alcoholic
simple steatosis
composition
stem cell
alcoholic steatohepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/008325
Other languages
French (fr)
Korean (ko)
Other versions
WO2019031729A2 (en
Inventor
이용원
조병성
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exocobio Inc
Original Assignee
Exocobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170162555A external-priority patent/KR20190015063A/en
Application filed by Exocobio Inc filed Critical Exocobio Inc
Publication of WO2019031729A2 publication Critical patent/WO2019031729A2/en
Publication of WO2019031729A3 publication Critical patent/WO2019031729A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a composition comprising a stem cell-derived exosome as an effective ingredient for preventing, relieving, alleviating, or treating non-alcoholic simple steatosis or non-alcoholic steatohepatitis. A composition of the present invention can prevent, relieve, alleviate, or treat non-alcoholic simple steatosis or non-alcoholic steatohepatitis by reducing or relieving fat accumulation or inflammation in hepatocytes or liver tissues, which acts as a cause of non-alcoholic simple steatosis or non-alcoholic steatohepatitis and by inducing the histological state of non-alcoholic simple steatosis or non-alcoholic steatohepatitis to moderate, improve, or change for the better.
PCT/KR2018/008325 2017-08-05 2018-07-24 Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis Ceased WO2019031729A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170099328 2017-08-05
KR10-2017-0099328 2017-08-05
KR1020170162555A KR20190015063A (en) 2017-08-05 2017-11-30 A composition comprising an exosome and/or extracellular vesicle derived from stem cell as an active ingredient and its application for improving non-alcoholic simple steatosis or non-alcoholic steatohepatitis
KR10-2017-0162555 2017-11-30

Publications (2)

Publication Number Publication Date
WO2019031729A2 WO2019031729A2 (en) 2019-02-14
WO2019031729A3 true WO2019031729A3 (en) 2019-05-16

Family

ID=65271734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/008325 Ceased WO2019031729A2 (en) 2017-08-05 2018-07-24 Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis

Country Status (1)

Country Link
WO (1) WO2019031729A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117384829A (en) * 2019-06-10 2024-01-12 布瑞克斯奥根株式会社 Compositions comprising interferon-gamma for promoting stem cell-derived exosome production and increasing dryness
EP4019027B1 (en) * 2019-08-22 2025-01-22 Brexogen Inc. Composition comprising exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells for prevention or treatment of non-alcoholic steatohepatitis
TWI836656B (en) * 2021-10-07 2024-03-21 中國醫藥大學 Use of exosomes derived from mesenchymal stem cells for treating non-alcoholic steatohepatitis
CN115386543B (en) * 2022-07-19 2024-02-02 长春科技学院 A kind of velvet antler stem cell exosome and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101501433B1 (en) * 2014-06-10 2015-03-11 주식회사 머쉬메드 A composition for prevention and treatment of non-alcoholic fatty liver disease
WO2016054094A1 (en) * 2014-09-30 2016-04-07 Research Institute At Nationwide Children's Hospital Compositions and methods for treating hepatic fibrosis
CN106974937A (en) * 2017-03-30 2017-07-25 山东大学 Application of the adipose-derived mescenchymal stem cell excretion body in treatment metabolic syndrome medicine is prepared

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101501433B1 (en) * 2014-06-10 2015-03-11 주식회사 머쉬메드 A composition for prevention and treatment of non-alcoholic fatty liver disease
WO2016054094A1 (en) * 2014-09-30 2016-04-07 Research Institute At Nationwide Children's Hospital Compositions and methods for treating hepatic fibrosis
CN106974937A (en) * 2017-03-30 2017-07-25 山东大学 Application of the adipose-derived mescenchymal stem cell excretion body in treatment metabolic syndrome medicine is prepared

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HU , LI ET AL.: "Exosomes Derived from Human Adipose Mensenchymal Stem Cells Accelerates Cutaneous Wound Healing via Optimizing the Characteristics of Fibroblasts", SCIENTIFIC REPORTS, vol. 6, 2016, pages 1 - 1 1, XP055485849, DOI: doi:10.1038/srep32993 *
LEE, YOUNG-SUN ET AL.: "Exosomes Derived from Palmitic Acid-treated Hepatocytes Induce Fibrotic Activation of Hepatic Stellate Cells", SCIENTIFIC REPORTS, vol. 7, no. 1, 16 June 2017 (2017-06-16), pages 1 - 10, XP055608796, ISSN: 2045-2322, DOI: 10.1038/s41598-017-03389-2 *

Also Published As

Publication number Publication date
WO2019031729A2 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
WO2019031729A3 (en) Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis
JOP20220243A1 (en) Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders
WO2019004757A3 (en) Use of composition comprising stem cell-derived exosome as effective ingredient for prevention or alleviation of pruritus
AU2018246796A1 (en) S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis
MX2021010350A (en) Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising leuconostoc citreum wikim0104.
EP3860619A4 (en) Compositions and methods for the treatment of pathogenic infections in plants
WO2019004738A3 (en) Use of composition comprising adipose stem cell-derived exosome as effective ingredient in alleviating dermatitis
PH12017500706A1 (en) Composition containing extract or fraction of genus justicia plant
PH12021551297A1 (en) Pharmaceutical composition, comprising inhibitory peptide against fas signaling, for prevention or treatment of obesity, fatty liver, or steatohepatitis
PH12018000207B1 (en) A pharmaceutical composition for prevention of diet induced obesity
MX2025006615A (en) Methods for altering body composition
PH12017502081B1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
IL274810A (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
EP3737384A4 (en) Methods and compositions for preventing and treating conditions related to alpha-synuclein
EP3773466A4 (en) Topical composition comprised of cod liver oil for treating wounds and skin disorders
WO2018074862A3 (en) Pharmaceutical composition comprising tha as active ingredient for treating breast cancer
EP3723766A4 (en) Composition and method for treating, relieving or preventing muscle cramps, containing choline alfoscerate as active ingredient
EP3762005A4 (en) Synergistic herbal compositions for the treatment of obesity and overweight
PL3727397T3 (en) Composition and method for treating, relieving or preventing neuropathic pain, containing choline alfoscerate as active ingredient
WO2019059549A3 (en) COMPOSITION FOR RELIEVING HANGOVER OR COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING ALCOHOLIC LIVER DISEASE, COMPRISING β-GLUCAN AS ACTIVE INGREDIENT
WO2016188932A3 (en) Combination of trpm8-agonist and nachr-agonist for treatment of obesity and related disorders and for weight reduction
PH12016501448A1 (en) Antifungal composition
KR102459998B9 (en) 1- Novel 1-tetralone chalcone and composition for preventing or treating inflammatory disease comprising the same as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18843917

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18843917

Country of ref document: EP

Kind code of ref document: A2